Please ensure Javascript is enabled for purposes of website accessibility

2 Reasons Why Exact Sciences Corporation Shareholders Were Clobbered in 2015

By Sean Williams - Jan 7, 2016 at 1:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Expected to launch out of the gate, Cologuard's growth was a major disappointment to Wall Street and investors in 2015.

EXAS Chart

Shares of Exact Sciences (EXAS 0.83%), the creator and manufacturer of the Cologuard diagnostic test, which is designed to detect colorectal cancer and advanced adenomas, plunged by two-thirds (66%) in 2015 based on data from S&P Capital IQ. The culprits behind the significant move lower? Look no further than Cologuard's less-than-stellar launch and the federal government continuing to pare back Medicare reimbursements.

When Cologuard was launched in 2014, and the product not long after received reimbursement approval from Medicare, the assumption was that it would storm out of the gate. With Medicare footing a large portion of the bill, it was believed that seniors would jump at the chance to get a non-invasive colorectal cancer screening. Unfortunately, the data shows that Cologuard's launch has been anything but blazing.

Based on Exact Sciences' third-quarter report, Cologuard generated just $12.6 million in revenue, and the company completed approximately 34,000 tests, a roughly 60% increase from the sequential second quarter. What remains a nuisance is the patient compliance rate of just 73%. The compliance rate is the number of completed tests based on the number of collection kits shipped to patients 60 or more days prior to the end of the quarter. In other words, 27% of patients aren't following through and sending their sample back to Exact Sciences. All told, Exact Sciences has lost $117.8 million in the first nine months of fiscal 2015.


Image source: Exact Sciences. 

The other issue here is that the federal government is looking for ways to reduce the reliance of private businesses on government-sponsored care. What this means is the expectation of Medicare reimbursement declines in the coming years. For example, a 2% reduction in Medicare fee-for-service claim payments has knocked the reimbursement rate for Cologuard down to $483.35 in 2016. With some of the cost for the test eventually getting pushed back to consumers, we have to wonder whether they'll pay it. 

But the big question is whether things will get better for Exact Sciences in 2016. My guess is to expect some modest improvement.

It takes a while to educate physicians and consumers about the diagnostic options available to them, and we're seeing a steady increase in diagnostic use over the last two quarters. Understandably, we're still not at a point where Exact Sciences can begin thinking about profitability, but we should begin to see its net loss and cash outflow move in the correct direction in 2016. There's a lot of potential here for the elderly to take advantage of a non-invasive diagnostic test that's considerably more accurate than its predecessor, but it'll take time and marketing spending on Exact Sciences' part to keep the ball rolling. This is an exciting company with long-tail growth potential that I currently have on my radar.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$42.71 (0.83%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
392%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.